Feb 17, 2017 at 15:29 | Source: Moneycontrol.com
Biocon shares gained 2.6 percent to hit a record high of Rs 1,123 after the US health regulator USFDA has accepted pharma major Mylan's biologics licence application (BLA) for MYL-1401H, a proposed biosimilar Pegfilgrastim.
Feb 17, 2017 at 15:22 | Source: CNBC-TV18
Market in yesterdays trade rallied owing to the gains from healthcare stocks. Swati Kulkarni of UTI MF said that pharma companies are going through the remediation process and after they US FDA approvals, the pharma stocks will perform well.
Feb 17, 2017 at 14:50 | Source: PTI
US health regulator USFDA hasaccepted pharma major Mylan's biologics licence application(BLA) for MYL-1401H, a proposed biosimilar Pegfilgrastim,Biocon and Mylan have said.
Feb 17, 2017 at 10:30 | Source: Moneycontrol.com
Brokerage firms and analysts tracking the stock welcomed the development and most have raised the target price. To be sure a lot of them were expecting resolution of the warning letter on Moraiya facility in the fourth quarter of FY17.
Feb 15, 2017 at 14:40 | Source: PTI
According to a notification issued by the US Food and Drug Authority, Dr Reddy's is recalling Olanzapine tablets USP of 2.5 mg while Aurobindo is recalling Pantoprazole Sodium for Injection, 40mg per vial from the market.
Feb 14, 2017 at 15:36 | Source: CNBC-TV18
During his campaign, US president Donald Trump vowed to ease the burden of the healthcare industry in US by reducing taxes and government regulations. Two important decisions expected from the Trump administration is appointment of Food and Drug Administration (FDA) commissioner and drug price control.
Feb 10, 2017 at 09:50 | Source: PTI
"This is to inform that our Paithan facility was recently inspected by the US FDA and we are issued one procedural related 483," Ajanta Pharma said in a BSE filing.
Feb 09, 2017 at 22:00 | Source: Moneycontrol.com
Laurus Laboratories posted a 17.5 percent increase in net profit to Rs 47.2 crore in the third quarter ended December on account of larger uptake of its API business.
Feb 09, 2017 at 20:17 | Source: Moneycontrol.com
The company said it plans to mitigate the any loss in revenue from Glumetza and Fortamet with over 25 potential launches in the next 12 months - including some big ones such as as birth-control pill Minastrin 24, HIV drug Epzicom, hepatitis-B medication viread, among others.
Feb 09, 2017 at 10:49 | Source: Moneycontrol.com
Ajanta Pharma Ltd has informed BSE that the Company's Paithan facility was recently inspected by US FDA and the Company has issued one procedural related 483. The Company is in process of responding to the same within the stipulated time prescribed by US FDA.